<乌鸦传媒>Add-On Venetoclax Promising in Younger, Fit AML Patients "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
<乌鸦传媒>IVF Babies at No Increased Risk of Childhood Cancers No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
<乌鸦传媒>Ethics Consult: Help Family Have 'Savior Child' for Marrow Donation? MD/JD Weighs In You voted, now see the results and an expert's discussion Jun 25, 2021
<乌鸦传媒>Fixed-Duration, All-Oral Regimen Slows CLL Progression Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
<乌鸦传媒>Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
<乌鸦传媒>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
<乌鸦传媒>Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patients BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy Jun 07, 2021
<乌鸦传媒>CAR-T Drives High Response in Relapsed/Refractory ALL ZUMA-3 study shows brexucabtagene autoleucel offers long-term clinical benefit Jun 06, 2021
<乌鸦传媒>Combination Therapy Achieves High Response in Ph+ ALL Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
<乌鸦传媒>Combo Therapy Boosts Response in Hairy Cell Leukemia Complete response achieved in 26 of 30 patients with vemurafenib/rituximab May 12, 2021
<乌鸦传媒>Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
<乌鸦传媒>Whole-Genome Sequencing Makes a Case in Leukemia Study More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
<乌鸦传媒>Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemia Tocilizumab reduced severe cytokine release syndrome in children, young adults Mar 09, 2021
<乌鸦传媒>Ethics Consult: Refuse Treatment for Dictator? MD/JD Weighs In You voted, now see the results and an expert's discussion Jan 15, 2021
<乌鸦传媒>PARP Inhibitors Linked With Blood Cancer Risk Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020
<乌鸦传媒>Chemo-Free Combo Boosts PFS in First-Line CLL PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
<乌鸦传媒>Novel Agent Active in Refractory CML Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
<乌鸦传媒>Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL DFS at 1 year reaches 95% in patients with undetectable MRD Dec 06, 2020
<乌鸦传媒>Blood Cancers and COVID-19: 'A Medically Vulnerable' Group Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
<乌鸦传媒>These Forbes 400 Billionaires Made Their Fortunes in Healthcare 14 individuals, $66 billion in combined net worth Sep 24, 2020
<乌鸦传媒>Raising the Bar for Myelofibrosis Therapy Development Rational combinations, new targets, and a first-ever phase III trial with a survival endpoint Sep 14, 2020
<乌鸦传媒>Worse Blood Cancer Outcomes in Hispanics Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
<乌鸦传媒>Combination Ups Survival in Older AML Patients Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone Jun 17, 2020
<乌鸦传媒>Early Palliation: Boon for AML Patients on Intensive Chemo Intervention led to marked improvements in QoL, mental distress, end-of-life care Jun 02, 2020
<乌鸦传媒>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<乌鸦传媒>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<乌鸦传媒>Bringing Transplant to More Patients With AML Conditioning with radiolabeled antibody leads to successful transplantation in 84% of older patients Feb 25, 2020
<乌鸦传媒>New CAR-T Makes Case for Aggressive Lymphomas Largest trial to date shows 73% ORR, 53% CR, potential for outpatient treatment Feb 25, 2020
<乌鸦传媒>Stem-Cell Transplant Trial Ends in a Draw Similar PFS with haploidentical bone marrow, double unrelated umbilical cord blood Feb 24, 2020
<乌鸦传媒>Myeloablative Therapy Prevails in AML Transplant Study Better survival, fewer relapses compared with reduced-intensity conditioning Feb 21, 2020
<乌鸦传媒>Better Quality CR With One AML Therapy vs Another? Longer survival after CR/CRi with CPX-351 than with 7+3 in patients with AML-MRC Feb 21, 2020
<乌鸦传媒>Gains in Stem Cell Transplant Mortality Over Last 25 Years But outcomes still "far from perfect" Jan 20, 2020
<乌鸦传媒>Higher Risk of Shingles Seen in Patients With Certain Cancers Vaccine development may help with prevention of herpes zoster in this population Dec 31, 2019
<乌鸦传媒>Survival Bump With Oral AML Maintenance Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients Dec 10, 2019
<乌鸦传媒>IGHV-Unmutated CLL: Gene Signature May Predict Outcomes After First-Line FCR Prognostic tool may predict who is likely to achieve a relatively long remission Oct 15, 2019
<乌鸦传媒>FCR Still an Option in IGHV-Unmutated CLL? Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit Oct 08, 2019
<乌鸦传媒>Ibrutinib's Cardiotoxicity Comes Into Focus Study identifies new cardiac events linked to so-called targeted therapy Sep 25, 2019
<乌鸦传媒>Overall Survival Data in for Gilteritinib as AML Salvage Tx FLT3 Inhibitor tops chemotherapy in randomized trial Apr 01, 2019
<乌鸦传媒>Transplant No Help in Hypodiploid ALL Similar 5-year outcomes with or without HSCT, regardless of MRD status Mar 29, 2019
